biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
~185 kDa
species reactivity
human
concentration
1 mg/mL
technique(s)
indirect immunofluorescence: 1:100-1:200, western blot: 1:500-1:1000
isotype
IgG
immunogen sequence
(N-L-YP-YP-W)
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
phosphorylation (pTyr1221/pTyr1222)
Quality Level
Gene Information
human ... ERBB2(2064)
General description
Erb-b2 receptor tyrosine kinase 2 (ErbB2) or human epidermal growth factor receptor 2 (HER2), is encoded by the gene mapped to human chromosome 17. The encoded protein belongs to the family of epidermal growth factors. ErbB2 membrane protein is characterized with a cysteine-rich extracellular ligand-binding domain, a hydrophobic membrane spanning region, and an intracellular tyrosine kinase domain.This protein does not have a ligand, and it either forms heterodimers with other family members or homodimer with itself when expressed at very high levels, to get activated. ErbB2 is expressed at low level in normal tissues, but at high level in breast cancer tissues.
Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF, TGF-alpha and amphiregulin.
Immunogen
Peptide sequence around phosphorylation site of tyrosine1221/1222 (N-L-Y(p)-Y(p) -W), according to the protein ERBB2.
Biochem/physiol Actions
Erb-b2 receptor tyrosine kinase 2 (ErbB2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, over expression of this protein causes breast cancer. Heterodimer complex of ErbB2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of ErbB2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of ErbB2. This domain is missing in p95, a truncated form of ErbB2, and hence these cancer cells show resistance to trastuzumab. ErbB2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
HER2: biology, detection, and clinical implications.
Gutierrez C and Schiff R.
Archives of Pathology & Laboratory Medicine, 135, 55-62 (2011)
The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21, 382-389 (2016)
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP
Molecular Diagnosis & Therapy, 17, 85-99 (2013)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持